A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone with Background Dapagliflozin in Subjects with Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

开始日期2024-11-30

申办/合作机构

Resverlogix Corp.

NCT03160430 / Not yet recruiting临床1/2期

A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222

This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal Disease (ESRD) patients who receive hemodialysis as standard of care.
Part B of the study is a double-blind, placebo-controlled study in up to thirty six (36) ESRD patients receiving hemodialysis using a sequential cross-over design with RVX000222 at a daily oral dose of 100 mg b.i.d. (200 mg per day) or matching placebo in combination with SoC.
The primary objective of the study is to evaluate if treatment with RVX000222 in combination with standard of care (SoC) decreases plasma alkaline phosphatase in comparison to placebo and SoC.

开始日期2024-11-22

申办/合作机构

Resverlogix Corp.

NCT04915300 / Not yet recruiting临床2期

Apabetalone for Pulmonary Arterial Hypertension: a Phase 2 Clinical Study

Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged. Short term placebo-controlled randomized trials assessing PAH-specific monotherapy with these molecules have reported improvements in pulmonary hemodynamics and exercise capacity. A recent meta-analysis also documented a reduction in short-term mortality of about ≈40% with such therapies. Several randomized clinical trials evaluating PAH-specific combination therapy have been conducted. Our recent meta-analysis showed that combination therapy was associated with a 35% risk reduction for the occurrence of clinical worsening compared to monotherapy. Nonetheless, the investigators also showed 17% of PAH patients receiving combination therapy still experienced clinical worsening over a median exposure of 16 weeks. Moreover, long-term survival on PAH-specific also therapy remains poor in the modern era, with a yearly mortality rate of 15 % in incident idiopathic PAH. The identification of innovative therapeutic targets and validation of these complementary therapeutic interventions are thus urgently needed in PAH.
The investigators and others (K. Stenmark, University of Colorado and H. Bogaard, VU University Medical Center, Amsterdam, personal communications), have published strong evidence that BRD4 plays a key role in the pathological phenotype in PAH accounting for disease progression and showed that BRD4 inhibition can reverse PAH in several animal models. Intriguingly, coronary artery disease (CAD) and metabolic syndrome are more prevalent in PAH compared with the global population, suggesting a link between these diseases. Interestingly, BRD4 is also a trigger for calcification and remodeling processes and regulates transcription of lipoprotein and inflammatory factors, all of which are important in PAH and CAD. Apabetalone, an orally available BRD4 inhibitor, is now in a clinical development stage with a good safety profile.
The overall objective of the study is to explore the efficacy and safety of apabetalone as an add-on therapy for adult PAH patients and to inform the conduct and the design of a Phase 3 trial.
The primary objective of the study is to assess the efficacy of apabetalone as evaluated by the change in PVR over a period of 24 weeks compared to placebo in adult subjects with PAH on stable background therapy.
Secondary objectives include changes at week 24 in 6MWD, plasma NT-proBNP concentration, WHO functional class, ESC/ERS risk stratification score, health-related quality of life and additional hemodynamic data from right heart.
Exploratory objectives are to evaluate the effects of apabetalone compared to placebo in adult subjects with PAH on mortality and clinically relevant morbidity events, and on circulating levels and transcription changes in whole blood markers of metabolism, vascular calcification, inflammation, DNA damage and leucocyte expression of BMPR2.

开始日期2023-10-01

申办/合作机构

Université Laval

[+2]

100 项与 Apabetalone 相关的临床结果

登录后查看更多信息

100 项与 Apabetalone 相关的转化医学

登录后查看更多信息

100 项与 Apabetalone 相关的专利（医药）

登录后查看更多信息

项与 Apabetalone 相关的文献（医药）

2024-11-01·PHARMACOLOGICAL RESEARCH

Commentary on "Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis".

Letter

作者: Xia, Xue ; Tong, Ying ; Li, Kaiqing ; Fu, Tong

A review.A review discussing role of the BET protein inhibitor Apabet- alone in attenuating kidney injury by targeting BRD4 protein to regulate the P300/H3K27ac/PLK1 axis and inhibiting NLRP3 inflammasome activation and cellular pyroptosis.It also discusses pharmacol. and genetic approaches to explore the effects of Apabetalone on cellular juxtaposition in a db/db mouse model and human renal tubular epithelial cells and found that Apabetalone or BRD4 siRNA could inhibit PLK1 in HK-2 cells.

2024-10-01·PHARMACOLOGICAL RESEARCH

Exploring the therapeutic potential of apabetalone in diabetic kidney disease: Bridging preclinical findings with clinical translation

Letter

作者: Shen, Wei ; Zhao, Guo ; Yao, Yi ; Wang, Wenhua ; Luo, Honglian

2024-10-01·PHARMACOLOGICAL RESEARCH

Correspondence: Reply to commentary on “Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis”

Letter

作者: Huang, Zhaohui ; Wang, Min ; Fan, QiuLing

A polemic response to Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300/H3K27ac/PLK1 axis.First, we performed randomized grouping by the random number table method.One of type 2 diabetic patient had a UACR of less than 30 mg/g and an eGFR of 55 mL/min/1.73 m2, and his renal biopsy pathol. was that of type 2 DKD, with KW nodules visible, and so was a non-proteinuric diabetic kidney disease.DKD is a heterogeneous disease.Although animal models have played an important role in promoting the study of DKD, it must be pointed out that the incidence of DKD in animals and humans is not uniform.Apabetalone improves UACR levels in db/db mice, without affecting changes in body weight and hyperglycemia.PLK1 expression was found to be increased in renal biopsies of DKD patients, kidney tissue of diabetic db/db mice and in HG-treated HK-2 cells.Our results revealed that apabtalone inhibits PLK1 expression through BRD4, attenuating cell pyroptosis, inflammation, and fibrosis and thus exerts a protective role.Our current study is a pilot study and have a lot of limitations.We will continue to do the clin. trials as your kindly and valuable comments.

项与 Apabetalone 相关的新闻（医药）

2024-05-28

·BioSpace

Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Calgary, Alberta--(News - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024. A Notice of Meeting and Management Information Circular, containing the matters to be considered at the Meeting, will be delivered to shareholders and filed on SEDAR+ at . Following the formal business of the Meeting, a corporate update presentation will be provided. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the upcoming Annual and Special Meeting of Shareholders and the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: To view the source version of this press release, please visit

2024-02-22

·BioSpace

Resverlogix Announces Change to Its Board of Directors.

Calgary, Alberta--(News - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's President and CEO. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit

高管变更

2024-02-06

·生物制药小编

“小分子“开发“大分子”靶标

近一个世纪，小分子药物一直是制药行业的中流砥柱。小分子药物被定义为低分子量（＜1000Da）的有机化合物，作为治疗药物具有一些明显的优势：大多数可以口服给药，并且可以穿过细胞膜到达细胞内靶标。还可以被设计成通过各种作用模式与生物靶点接触，它们的分布可以进一步定制，例如允许在有或没有大脑穿透的情况下进行全身暴露。随着Humira、Keytruda、Stelara等生物制剂不断刷新销售记录，制药公司在药物开发选择方向上越来越多地面临“小分子还是生物制剂”的选择。尽管生物制剂取得了显著的成就，但小分子药物仍然在行业中占据统治地位。随着技术的更新，小分子药物也在不断创造新的发展条件。下面小编将带大家一起对小分子药物进行一次全面的认识。小分子药物开发的优势和挑战小分子药物开发是目前药物研发领域的主流，其具有许多优势和挑战。优势：①首先，小分子药物具有较小的分子量和较简单的化学结构，这使得它们易于合成和修改，从而提高了药物开发的效率。②此外，小分子药物通常具有较好的口服生物利用度，可以通过口服给药途径进行治疗，提高患者的便利性和治疗依从性。挑战：①首先，小分子药物往往具有较短的半衰期，需要频繁的给药以维持治疗效果。②此外，小分子药物通常具有较高的代谢和排泄速率，容易被机体代谢和清除，从而限制了其在体内的持续作用时间。③此外，小分子药物的选择性和特异性较低，容易与其他分子发生非特异性相互作用，导致副作用的发生。尽管面临一些限制，小分子药物仍然是目前药物研发的主要方向，其在临床应用和市场上具有广泛的应用前景。开发大分子靶标的意义大分子靶标是指具有较大分子量的蛋白质或其他生物大分子，其特点和应用领域在药物开发中具有重要意义。大分子靶标通常具有复杂的结构和功能，与小分子靶标相比，其药物开发过程更加复杂和挑战性。首先，大分子靶标具有更高的特异性。由于其复杂的结构和功能，大分子靶标通常具有更高的特异性，能够更精确地与药物相互作用。这使得大分子靶标在疾病治疗中具有更好的选择性，能够减少对正常细胞的不良影响。其次，大分子靶标在药物开发中具有更广泛的应用领域。大分子靶标在多个疾病领域中发挥着重要作用，如癌症、免疫系统疾病、神经系统疾病等。通过针对大分子靶标的药物开发，可以实现对这些疾病的精准治疗，提高治疗效果和患者生活质量。此外，大分子靶标在临床应用中具有一定的挑战性。由于大分子药物的复杂性和制备难度，其临床应用往往面临一些挑战。例如，大分子药物的制备成本较高，需要更复杂的生产工艺和设备。此外，大分子药物在体内的稳定性和药代动力学也需要更多的研究和优化。小分子药物开发大分子靶标近期发表在C&EN上的一篇文章展望了小分子药物的前景。文章认为小分子药物的开发将迎来一个新的阶段，且在医药领域发挥重要作用。分子胶和PROTAC等新型小分子药物也正在不断向前发展以推动人类疾病治疗。此外，人工智能的应用也将直接推动小分子药物的设计和开发。图注：2013-2022年间FDA批准药物的对比。图片来源：C&EN目前CD33、CD30、HER2、CD22、CD79b、Nectin-4、BCMA、EGFR、CD19、TissueFactor和FRα等靶点已经是上市小分子药物的成熟靶点，在研靶点包括HER2、EGFR、CLDN18.2、TROP2、c-Met、CD19、PSMA、Muc1、BCMA和PDL1。目前在开发大分子靶标方面，有许多小分子正在被研究和开发：● 抗癌药物：包括靶向蛋白激酶的小分子抑制剂，如吉非替尼（Gefitinib）和厄洛替尼（Erlotinib）用于EGFR阳性非小细胞肺癌的治疗；以及靶向蛋白酶的小分子抑制剂，如伊马替尼（Imatinib）用于慢性髓性白血病的治疗。● 免疫调节药物：包括靶向免疫检查点的小分子抑制剂，如伊普替尼（Ipilimumab）和尼伦帕尼布（Nivolumab）用于恶性黑色素瘤的治疗。● 炎症性疾病药物：包括靶向炎症介质的小分子抑制剂，如阿帕替尼布（Apabetalone）用于治疗心血管疾病。● 病毒感染药物：包括靶向病毒复制过程的小分子抑制剂，如奥司他韦（Oseltamivir）用于流感病毒感染的治疗。● 神经系统疾病药物：包括靶向神经递质受体的小分子调节剂，如多巴胺受体激动剂用于帕金森病的治疗。共价抑制剂、蛋白质降解技术（如PROTAC）、分子胶、分子门、人工智能的发展为小分子药物设计和开发提供了更多的模式与方法，有望加速新药的推出并降低研发的成本。图注：海外临床在研PROTAC药物（资料来源：安信证券研究中心）图注：国内临床在研PROTAC药物（资料来源：安信证券研究中心）根据Mordor Intelligence的报告，小分子药物发现市场预计将在2023年达到523.5亿美元，并以年增长率8.76%增长，到2028年将达到796.7亿美元。一些公司如ICON Plc、Charles River Laboratories和Labcorp在该市场上扮演重要角色。根据X-MOL的报道，2022年药物销售业绩Top 10中，生物制剂占据了6个位置，小分子药物占据了4个位置。但是考虑到生物制剂的生产成本较高，总体来说，小分子的成绩或许更亮眼。根据在Medicine in Drug Discovery 上发表的一篇文章，小分子仍处于创新药物研发的范畴，在全球范围内销售的所有药物中，约 90% 是小分子，其RNA靶向活性、抑癌活性、抗病毒活性等逐步被发掘，此外在考虑成本以及受众群体再到新技术开发等方面，小分子仍然在治疗领域占据不可替代的地位。在 FDA 2017-2022 年批准的 293 个新化学实体（NCE）中，182 个是小分子。不论是从数量上还是从市场实际情况上来看，小分子药物依然占据医药市场的统治地位。未来发展方向和挑战小分子药物开发大分子靶标领域一直面临着许多挑战，但也有着广阔的发展前景。未来的发展方向将主要集中在以下几个方面：● 靶向多靶点治疗：随着对疾病机制的深入研究，我们发现许多疾病是由多个靶点的紊乱引起的。因此，未来的小分子药物开发将更加注重靶向多个靶点的治疗策略，以提高治疗效果。● 靶向特定亚型：许多疾病的发展与特定亚型的靶标有关。因此，未来的研究将更加注重发现和开发针对特定亚型的小分子药物，以实现个体化治疗。● 结构优化和药物设计：小分子药物的结构优化和药物设计是提高药物疗效和减少副作用的关键。未来的发展将更加注重利用计算机辅助药物设计和结构优化技术，以提高药物的选择性和亲和力。● 新技术的应用：随着科技的不断进步，新技术的应用将为小分子药物开发带来新的机遇。例如，基因编辑技术和纳米技术的应用将为小分子药物的靶向性和传递性提供更多可能性。然而，小分子药物开发在大分子靶标领域仍然面临着一些挑战：● 靶标的复杂性：大分子靶标通常具有复杂的结构和功能，这给小分子药物的开发带来了挑战。因此，研究人员需要深入了解靶标的结构和功能，以寻找合适的小分子药物。● 药物递送：大分子靶标通常位于细胞内或细胞膜上，而小分子药物需要通过细胞膜进入细胞内才能发挥作用。因此，药物的传递性是一个重要的挑战，需要寻找合适的传递载体或技术。● 药物耐受性和副作用：小分子药物的耐受性和副作用是开发过程中需要考虑的重要因素。研究人员需要寻找具有较低副作用和良好耐受性的小分子药物。● 临床试验的挑战：大分子靶标的临床试验通常需要更长的时间和更高的成本。因此，研究人员需要克服临床试验的挑战，以确保药物的安全性和有效性。总的来说，小分子药物开发大分子靶标领域面临着许多挑战，但也有着广阔的发展前景。通过针对多靶点治疗、靶向特定亚型、结构优化和药物设计以及新技术的应用，我们有望开发出更加有效和安全的小分子药物，为疾病治疗带来新的突破。然而，我们需要克服靶标的复杂性、药物传递性、药物耐受性和副作用以及临床试验的挑战，以实现小分子药物在大分子靶标领域的应用和推广。参考文章：1.A big future for small molecules: targeting the undruggable，AstraZeneca，August 2022， 2.Small Molecules，B. Lu, A. Atala, in In Situ Tissue Regeneration, 2016， 3.Visualizing molecular glues，Elizabeth Dougherty，Mar 27, 2020， 4.Makurvet, F. D. et. al. Biologics vs. small molecules: Drug costs and patient access. Med. Drug Discov., 2021, 9, 100075.5.ls this a golden age of small-molecule drug discovery? pubs.acs.org/doi/10.1021/cen-10136-cover6.Small molecules are sexy again’ : Gate Bioscience debuts with 560M and a new way to stop disease-causing proteins

100 项与 Apabetalone 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11131	Apabetalone	-	DB12000

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
新冠肺炎后遗症	临床3期	约旦	Resverlogix Corp.	2024-11-30
新冠肺炎后遗症	临床3期	沙特阿拉伯	Resverlogix Corp.	2024-11-30
新冠肺炎后遗症	临床3期	阿拉伯联合酋长国	Resverlogix Corp.	2024-11-30
新型冠状病毒感染	临床3期	加拿大	Resverlogix Corp.	2022-01-14
冠心病	临床3期	阿根廷	Resverlogix Corp.	2015-11-01
冠心病	临床3期	澳大利亚	Resverlogix Corp.	2015-11-01
冠心病	临床3期	比利时	Resverlogix Corp.	2015-11-01
冠心病	临床3期	保加利亚	Resverlogix Corp.	2015-11-01
冠心病	临床3期	克罗地亚	Resverlogix Corp.	2015-11-01
冠心病	临床3期	德国	Resverlogix Corp.	2015-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02586155 (BETonMACE, ERA2023)	临床3期	慢性肾病	-	Apabetalone 100 mg	範鹽糧鏇觸蓋觸構選夢(範範築蓋夢壓蓋積糧鑰): HR = 0.5 (95% CI, 0.26 ~ 0.96), P-Value = 0.04	积极	2023-06-14
				Placebo
BETonMACE2 \| BETonMACE (ASN2021)	临床3期	-	-	Apabetalone 1-25 µ M	餘網選蓋鬱觸膚鏇鹹蓋(顧遞衊築顧簾蓋遞選衊) = 築鹽艱夢壓醖蓋夢膚鏇鑰鏇鹹簾夢繭糧簾選襯 (憲構積簾夢選願網醖膚 ) 更多	积极	2021-10-27
NCT03655704 (APPRoAcH-p, GlobeNewswire) 人工标引	临床1期	肺动脉高压	7	Apabetalone	膚獵遞鏇鹽襯壓憲積網(餘觸鹽製襯憲糧築觸襯) = improved 膚選壓鏇壓鑰蓋積範積 (憲餘築艱繭鬱觸顧鹹壓 )	积极	2021-09-08
NCT02586155 (BETonMACE, CTgov)	临床3期	2型糖尿病 \| 冠心病	2,425	rosuvastatin+atorvastatin+Apabetalone (High-Intensity Statin Therapy+RVX000222)	鹹鬱鹹淵積製壓簾襯廠(艱艱願製鏇膚餘顧網夢) = 範糧壓夢範範壓積艱鹽網襯夢齋醖餘夢膚築鹹 (簾廠襯鏇鑰繭遞艱構膚, 衊醖築廠顧選鑰醖鏇廠 ~ 鹽衊選壓積餘膚觸憲壓) 更多	-	2021-08-20
				Placebo+rosuvastatin+atorvastatin (High-Intensity Statin Therapy+Placebo)	鹹鬱鹹淵積製壓簾襯廠(艱艱願製鏇膚餘顧網夢) = 鏇簾範廠網鏇糧鏇蓋鏇網襯夢齋醖餘夢膚築鹹 (簾廠襯鏇鑰繭遞艱構膚, 憲襯網鑰鹹夢鏇顧醖衊 ~ 膚範鑰顧願製壓廠積獵) 更多
BETonMACE \| BETonMACE2 (ERA2021)	临床3期	慢性肾病	-	APABETALONE (TGF-β1)	築鹹蓋簾蓋鑰衊選窪襯(遞夢簾築簾製鏇蓋範夢) = 鬱獵獵願構繭醖觸觸壓襯製醖淵糧願醖衊構淵 (顧構觸鹹艱憲廠製鏇淵 ) 更多	积极	2021-05-29
				APABETALONE (LPS)	(繭構鹽願憲鏇範積醖齋) = 醖壓醖願廠衊鏇範製鏇憲夢願繭窪艱繭蓋選齋 (製顧窪願觸艱網窪鑰積 )
AAI2021	N/A	法布里病	-	Apabetalone	範繭鏇顧夢淵遞夢廠遞(糧蓋願選廠簾鏇齋淵鏇) = 選蓋鑰簾遞壓簾壓構鑰窪網鑰襯夢夢膚鑰夢醖 (壓顧壓鹽範遞蓋衊繭範 )	-	2021-05-01
BETonMACE (ASN2020)	临床3期	-	2,425	Apabetalone	淵餘餘網顧艱憲醖鏇構(鬱壓製蓋築顧衊齋糧製) = 窪膚蓋鹽鹽積廠鑰衊夢觸壓鹹廠鑰選繭憲憲壓 (醖膚築顧簾積夢顧遞鬱, 1.67 ~ 3.44) 更多	积极	2020-10-19
				Placebo	淵餘餘網顧艱憲醖鏇構(鬱壓製蓋築顧衊齋糧製) = 餘觸範齋顧獵願膚築獵觸壓鹹廠鑰選繭憲憲壓 (醖膚築顧簾積夢顧遞鬱, 1.67 ~ 3.44) 更多
BETonMACE (ERA2020)	临床3期	2型糖尿病 \| 急性冠状动脉综合征 \| 慢性肾病	2,425	Apabetalone (ABP)	鹹願範淵鏇選鬱獵襯醖(觸鏇觸襯繭獵衊簾繭衊) = 鏇顧鹽夢鹽蓋憲鏇獵積艱獵範遞製齋餘選糧鹹 (醖鬱襯鑰膚鹽顧製齋廠 )	积极	2020-06-06
				Placebo (PBO)	鹹願範淵鏇選鬱獵襯醖(觸鏇觸襯繭獵衊簾繭衊) = 繭積襯製艱構窪蓋願鹹艱獵範遞製齋餘選糧鹹 (醖鬱襯鑰膚鹽顧製齋廠 )
NCT02586155 (BETonMACE, Pubmed \| J Coll Physicians Surg Pak \| JAMA) 人工标引	临床2期	2型糖尿病 \| 急性冠状动脉综合征	2,425	Apabetalone	簾繭製遞選糧壓蓋襯構(鏇鑰鏇獵鹽築齋製壓憲) = 築壓網蓋夢淵築餘築壓餘廠夢醖膚憲選糧鹽遞 (醖選糧艱鹹製淵鹽鏇築 ) 更多	不佳	2020-04-28
				Placebo	簾繭製遞選糧壓蓋襯構(鏇鑰鏇獵鹽築齋製壓憲) = 窪繭鹹鑰簾觸蓋餘簾鬱餘廠夢醖膚憲選糧鹽遞 (醖選糧艱鹹製淵鹽鏇築 ) 更多
NCT02586155 (BETonMACE, Pubmed \| Am Heart J)	临床3期	急性冠状动脉综合征 \| 糖尿病	2,425	Apabetalone 100 mg	製製醖鑰鹽壓簾選衊願(積繭糧選顧醖窪衊鏇蓋) = 選鑰構齋蓋夢遞觸艱餘醖鏇觸遞構鹽廠餘鬱鑰 (鹽蓋鹽廠鹹夢襯艱膚鏇 )	-	2019-11-01